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Background: Assessments of health-related quality of life and particularly utility values are important components
of health economic analyses. Several instruments have been developed to measure utilities. However no consensus
has emerged regarding the most appropriate instrument within a therapeutic area such as chronic pain. The study
compared two instruments – EQ-5D and SF-6D – for their performance and validity in patients with chronic pain.
Methods: Pooled data from three randomised, controlled clinical trials with two active treatment groups were
used. The included patients suffered from osteoarthritis knee pain or low back pain. Differences between the utility
measures were compared in terms of mean values at baseline and endpoint, Bland–Altman analysis, correlation
between the dimensions, construct validity, and responsiveness.
Results: The analysis included 1977 patients, most with severe pain on the Numeric Rating Scale. The EQ-5D
showed a greater mean change from baseline to endpoint compared with the SF-6D (0.43 to 0.58 versus 0.59 to
0.64). Bland–Altman analysis suggested the difference between two measures depended on the health status of a
patient. Spearmans rank correlation showed moderate correlation between EQ-5D and SF-6D dimensions. Construct
validity showed both instruments could differentiate between patient subgroups with different severities of adverse
events and analgesic efficacies but larger differences were detected with the EQ-5D. Similarly, when anchoring the
measures to a disease-specific questionnaire – Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) – both questionnaires could differentiate between WOMAC severity levels but the EQ-5D showed greater
differences. Responsiveness was also higher with the EQ-5D and for the subgroups in which improvements in
health status were expected or when WOMAC severity level was reduced the improvements with EQ-5D were
higher than with SF-6D.
Conclusions: This analysis showed that the mean EQ-5D scores were lower than mean SF-6D scores in patients
with chronic pain. EQ-5D seemed to have higher construct validity and responsiveness in these patients.
Keywords: Quality of life, Chronic pain, Tapentadol, Utility, Health technology assessment, Cost effectiveness,
Cost utility, Health economics* Correspondence: hiltrud.liedgens@grunenthal.com
Grunenthal GmbH, Zieglerstrasse 6, Aachen 52099, Germany
© 2013 Obradovic et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Obradovic et al. Health and Quality of Life Outcomes 2013, 11:110 Page 2 of 9
http://www.hqlo.com/content/11/1/110Background
Chronic pain represents a major health burden in Europe
affecting as many as one in five adults [1-3] Pain can be
directly related to absenteeism and unemployment, and
severe daily pain has been shown to increase healthcare
resource utilization with increased visits to healthcare
providers, including hospitalisations [4-6]. It also has a
major impact on an individual’s quality of life [6] which
can substantially decrease with increasing pain severity
[7]. Many patients with chronic pain report being less
able, or no longer able, to take part in various daily ac-
tivities, such as walking, driving, working outside home,
sleeping, etc. [2].
The impact of both illness and treatment of illness on
quality of life is increasingly measured using quality ad-
justed life years (QALYs) and ‘utility’ scores that repre-
sent people’s preferences towards a particular health
state. A utility is a metric used in health economic evalu-
ations to capture quality of life and is used as a basis of
cost-utility analysis, the most common type of health
economic evaluation used in health technology assess-
ment. Utilities are measured on an interval scale from
zero to one; zero reflects states of health equivalent to
death and one reflects full health. The utility score is
based on the definition and description of a set of health
states together with the valuation of those health states
according to the strength of preference for each. Direct
measurement of utilities can be undertaken for any
health state. The two classical direct measurement tech-
niques are the standard gamble (SG) and the time trade-
off (TTO). The SG estimates utility of a particular health
state based on the maximum risk of immediate death
that an individual is willing to accept in order to gain
full health. The TTO estimates utility based on the life
time an individual is willing to give up for a shorter
period in full health. Thus, there is a systematic differ-
ence in utilities derived from SG and TTO. However,
these methods are time-consuming, complex and at
times, may not be ethical [8]. As a result, indirect meas-
urement of utilities is more commonly undertaken by
using pre-scored, multi-attribute health status classifica-
tion systems [9]. These generic instruments include the
EuroQol-5 dimension (EQ-5D), Short Form-6 dimension
(SF-6D), and Health Utilities Index 3 (HUI3) and gener-
ate utilities that can be used to compare QALYs across
different patient groups and diseases.
The EQ-5D, SF-6D and HUI3 differ considerably in
terms of their dimensions, items and preference weights
[8] and there is no consensus on which of these is best
or most useful in individual conditions including in
chronic pain. The EQ-5D tends to be the measure most
used in cost-utility analysis and in health technology as-
sessment; for example the use of QALYs is required by
the National Institute for Health and Clinical Excellence(NICE) in the UK with the EQ-5D as the preferred
measure of utility [10]. Alternative measures can be used
if there is evidence that EQ-5D is not suitable for a par-
ticular patient group [10].
The EQ-5D is a standardised instrument for use as a
measure of health outcome developed by the EurolQol
group, a consortium of investigators in Europe [11]. It is
applicable to a variety of different illnesses and treat-
ments and provides a simple descriptive profile and a
single index value for health status. The five dimensions
included in the EQ-5D are: mobility; self-care; usual ac-
tivities; pain/discomfort and anxiety/depression. Each di-
mension has three levels (no problems, some problems,
major problems) and together defines 243 health states
(3 to the power of 5 gives the 243 possible combination),
to which has been added “unconscious” and “dead” for a
total of 245 health states. There are a number of
country-specific scoring functions available which allow
derivation of utilities specific to certain settings. In the
UK, for example, a utility score is assigned to each
health state based on the preferences elicited from a sur-
vey of 3395 adults by using the time trade-off method
[12]. EQ-5D scores range between −0.594 and 1 (full
health).
The SF-6D is derived from the health-related quality
of life questionnaire, the Short Form 36 [13]. It has six
dimensions: physical functioning; role limitations; social
functioning; pain; mental health and vitality; the classifi-
cation system consists of four to six levels on each of the
six attributes, giving a total of 18,000 health states. The
SF-6D comes with a set of preference weights obtained
from a sample of the general population in the UK using
the standard gamble valuation technique [13].
Here we report an analysis undertaken to compare the
performance and validity of EQ-5D versus SF-6D in pa-
tients with chronic pain due to osteoarthritis of the knee
or low back pain based on data from three similar phase
III trials [14]. The two measures were possible to com-
pare because the EQ-5D and SF-36 (from which SF-6D
is derived) were both used in these studies.
Methods
This study analysed data pooled from three randomised,
controlled studies [14]. All three trials had similar de-
sign; randomised, multicentre, double-blind, parallel-
group, placebo-controlled, and active controlled. Eligible
patients included both men and women with a clinical
diagnosis of either osteoarthritis knee pain (two studies;
ClinicalTrials.gov Identifiers NCT00421928 [15], and
NCT00486811) or non-malignant low back pain (one
study; ClinicalTrials.gov Identifier NCT0044917615 [16]).
Patients had been taking analgesics for the pain for at least
three months, and were dissatisfied with their current anal-
gesic therapy. The inclusion criteria mandated patients to







release (n = 978) release (n = 999)
Mean ± SD age, years 56.8 ± 12.22 56.7 ± 12.39
Age category, n (%):
<65 years 719 (73.5) 731 (73.2)
≥65 years 259 (26.5) 268 (26.8)
Gender, n (%)
Female 639 (65.3) 601 (60.2%)
Male 339 (34.7) 398 (39.8)
Race, n (%)
White 803 (82.1) 813 (81.4)
Black 111 (11.3) 101 (10.1)
Hispanic 40 (4.1) 58 (5.8)
Other 24 (2.5) 27 (2.7)
Pain condition, n (%)
Osteoarthritis knee pain 663 (67.8) 673 (67.4)
Low back pain 315 (32.2) 326 (32.6)
Mean ± SD pain
intensity score *+
7.4 ± 1.26 7.3 ± 1.21
Pain intensity category,
n (%) + ~
Mild 2 (0.2) 0
Moderate 119 (12.2) 123 (12.3)
Severe 854 (87.6) 873 (87.7)
Prior opioid experience,
n (%)
No 641 (65.5) 681 (68.2)
Yes 337 (34.5) 318 (31.8)
*Average pain score (11 point numerical rating scale) recorded over the last 72
hours prior to randomisation.
+ Tapentadol n = 975, oxycodone n = 996.
~ Mild pain intensity defined as 1 to <4 on the numerical rating scale,
moderate >4 to <6 and severe ≥6.
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11-point numerical rating scale (NRS; 0 = ‘no pain’ to
10 = ‘pain as bad as you can imagine‘). Patients re-
ceived twice daily doses of placebo, tapentadol PR
(100–250 mg), or oxycodone HCl CR (20–50 mg) for
a 12-week maintenance period, preceded by a 3-week
titration period. Primary endpoints were change from
baseline in average pain intensity at week 12 of the
maintenance period and for the overall maintenance
period. Secondary endpoints included the SF-36 health
survey and the EQ-5D health survey.
This analysis combined data from all the patients in
the two active treatment groups and compared the mean
values of the EQ-5D and SF-6D at baseline and end-
point, as well as exploring differences between the two
measures using a Bland–Altman plot. This is a statistical
method that uses a graphical presentation to illustrate
how differences between two measures depend on the
health status of a patient [17]. Combined data were also
used to compare distributions across severity levels of
the EQ-5D and SF-6D dimensions and correlations
across dimensions using Spearman’s rank coefficient.
Construct validity was undertaken to test the ability of
each instrument to distinguish between known sub-
groups. In one analysis the ability of the two utility mea-
surements to discriminate between health states with
different severities of adverse events and analgesic effica-
cies was tested. A proportion of patients having experi-
enced an adverse event (typically constipation, nausea
and vomiting, dizziness, somnolence) discontinued treat-
ment as they found adverse events too bothersome.
Some patients discontinued treatment due to lack of ef-
ficacy and other patients tolerated the treatment well,
having no adverse events and completing the trial. Rates
of these events have been reported in Lange et al. 2010
[14]. Therefore, these subgroups represent different se-
verities of adverse events and analgesic efficacies of
treatments and can be used to test construct validity of
the two questionnaires compared. In another analysis,
the ability of each instrument to distinguish among
patient subgroups in the two osteoarthritis studies
which were shown to differ based on a disease specific
measure, i.e. anchoring to the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
was analysed. WOMAC is a standardised questionnaire
used to assess pain, stiffness, and physical function in
patients with hip and / or knee osteoarthritis [18]. The
WOMAC measures five items for pain (score range 0–
20), two for stiffness (score range 0–8), and 17 for func-
tional limitation (score range 0–68). The total WOMAC
score is created by summing the items for all three sub-
scales, with higher scores reflecting worse pain, stiffness,
and physical function. Based on the total score patients
were classified into four groups with increasing severitylevel: none to mild (total score of 0 to ≤24), mild to moder-
ate (total score of >24 to ≤48), moderate to severe (total
score of >49 to ≤72), and severe to extreme (total score
of >72 to ≤96). WOMAC’s reliability and validity have
been demonstrated in many countries [19].
The responsiveness or ability to detect improvements
(or deterioration) in a health state, of each instrument
was also analysed using the standardized response mean
(SRM). The SRM is the average difference divided by the
standard deviation of the differences between the paired
measurements. Improvements in the EQ-5D versus
the SF-6D utilities were measured for patients with
different severity levels based on the overall WOMAC
score at baseline versus study endpoint (for osteoarthritis
studies). Improvements in the EQ-5D compared with
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with different severities of adverse events and anal-
gesic efficacies.
Results
The analysis included a total of 1977 patients, the major-
ity of whom had severe pain (Table 1). Mean values for
baseline EQ‐5D and SF‐6D utilities compared with mean
values for endpoint showed a greater change from base-
line to endpoint with EQ-5D compared with SF-6D
(0.43 to 0.58 [mean change of 0.15; 95% CI: 0.143 -
0.169] versus 0.59 to 0.64 [mean change of 0.05; 95% CI:
0.045-0.055]). In addition these mean values highlighted
differences in scoring at baseline for each measurement
scale, with EQ-5D giving lower values.
The Bland–Altman plot for assessment of agreement
of the two methods of measurement suggested that the
differences between the two measurements depended on
the health status of the individual patient. Patients with
low quality of life (average utility <0.6) had lower scores
on the EQ-5D and, conversely, those with high quality of
life (average utility >0.8) had greater scores on the EQ-
5D. However, for those patients with mid-range utility
values, the EQ-5D and SF-6D were more aligned
(Figure 1).
In EQ-5D patients most frequently noted having se-
vere problems in “pain/discomfort” dimension and no
problems in “self care” and “anxiety/depression” dimen-
sions (Figure 2a). In SF-6D the most severe problems
were seen in “pain” and “physical functioning” dimen-
sions and least problems in “mental health”, “role limita-
tion” and “social functioning” (Figure 2b). Analysis of
correlation between EQ-5D and SF-6D dimensionsFigure 1 Bland Altman plot for EQ-5D and SF-6D scores at baseline.revealed a moderate correlation. Among the similar
dimensions, there was stronger correlation between
pain and pain/discomfort; mental health and anxiety/
depression; physical functioning and self-care; role limi-
tation and usual activities; social functioning and anxiety/
depression (Table 2). Vitality exists only for the SF-6D
and not surprisingly, therefore, it exhibited a weaker cor-
relation with EQ-5D dimensions.
Construct validity suggested that both questionnaires
could differentiate between patient subgroups in terms
of tolerating the treatment, having adverse events, dis-
continuing due to adverse events and discontinuing due
to lack of efficacy. Differences between subgroups were
larger in case of EQ-5D (Table 3). Additionally, both
questionnaires could differentiate between WOMAC se-
verity levels; the mean EQ-5D and SF-6D values de-
creased with increasing WOMAC severity levels which
is in line with expectations. The differences between
EQ-5D and SF-6D increased with increasing WOMAC
severity and showed the greatest difference in the severe
to extreme group (Table 3). The differences between
EQ-5D and SF-6D for more severe WOMAC states were
substantially larger than the minimal important differ-
ences (MID) of both questionnaires.
Responsiveness analysis suggested that improvements
in EQ-5D versus SF-6D utilities were higher with EQ-
5D. The EQ-5D had a higher standardized response
mean, especially for patients in the ‘severe to extreme’
level of overall WOMAC severity at baseline (Figure 3).
For the subgroups where there were expected improve-
ments in health status (patients who completed the trial
and had no adverse events or patients who com-
pleted the trial and had >30% pain relief ), the EQ-5D
Figure 2 Distribution across severity levels of the EQ-5D and SF-6D dimensions at baseline. (a) Distribution across severity levels of the
EQ-5D dimensions at baseline. (b) Distribution across severity levels of the SF-6D dimensions at baseline.
Table 2 Correlation between EQ-5D and SF-6D dimensions (using Spearman’s rank coefficient)
SF-6D dimensions
Pain Mental health Physical functioning Role limitation Social functioning Vitality
EQ-5D dimensions Pain/discomfort 0.46 0.11 0.22 0.18 0.25 0.21
Anxiety/depression 0.24 0.51 0.20 0.21 0.40 0.20
Mobility 0.23 0.10 0.24 0.19 0.18 0.10
Self care 0.22 0.21 0.41 0.17 0.29 0.13
Usual activities 0.37 0.13 0.29 0.030 0.30 0.20
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Table 3 Construct validity: comparison of EQ-5D and SF-6D in terms of patient subgroup differentiation and WOMAC




Patients who completed the trial and had no adverse events 0.695 0.694 0.001
Patients with at least one AE 0.583 0.640 −0.057
Patients with an AE that lead to withdrawal 0.503 0.594 −0.091
Patients who discontinued therapy due to lack of efficacy 0.405 0.582 −0.176
WOMAC severity level at baseline
None to mild 0.740 0.717 0.023
Mild to moderate 0.550 0.616 −0.066
Moderate to severe 0.311 0.536 −0.225
Severe to extreme 0.180 0.461 −0.281
Figure 3 Comparison of EQ-5D and SF-6D in terms of responsiveness. (a) Change in utility from different WOMAC categories at baseline to
‘none to mild’ at endpoint. (b) Change in utility from different WOMAC categories at baseline to ‘mild-to-moderate’ at endpoint.
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This was also seen for other subgroups; those experien-
cing adverse events, patients discontinuing due to ad-
verse events and patients discontinuing due to lack of
efficacy. For patients who discontinued therapy either
due to adverse events or lack of efficacy, the SF-6D
showed no change, whereas a slight improvement was
seen with the EQ-5D (Table 4).
Discussion
This study represents one of the larger analyses under-
taken to date comparing the EQ-5D and SF-6D and sug-
gests that the EQ-5D may be the more appropriate
technique for measurement of utility values in severe
chronic pain.
The results of this analysis suggested that the mean
EQ-5D scores were generally lower than mean SF-6D
scores in chronic pain and that the difference between
these two measures was dependent on the quality of life
status of individual patients. The differences in mean
utilities between patients with different severity levels
based on a disease-specific questionnaire (WOMAC)
were substantially larger with the EQ-5D compared with
the SF-6D. In addition, the EQ-5D had higher respon-
siveness; improvements utilities for patients with differ-
ent severity levels were higher with the EQ-5D. It also
detected larger differences between various health states
with different adverse events, severity and pain relief,
and produced larger changes in utility from baseline to
endpoint for these groups.
Similar results have been found in other studies, both
in patients with pain [20-23] and in other illnesses
[24,25]. In a cross-sectional study of 275 individuals with
chronic low back pain, Søgaard and colleagues found
that the mean value of EQ-5D was significantly lower
than that of the SF-6D, whereas the variation across ob-
servations was significantly greater for the EQ-5D [20].
They also found that the difference between measures
was associated with the average value of health, i.e., theTable 4 Comparison of EQ-5D and SF-6D in patient
subgroups where there were expected improvements in
health status




Patients who completed the trial and
had no adverse events
0.252 0.094
Patients who completed the trial and
had >30% pain relief
0.286 0.113
Patients with at least one AE 0.157 0.049
Patients with an AE that lead to
withdrawal
0.073 0.005
Patients who discontinued therapy
due to lack of efficacy
0.032 0.006poorer the health, the higher the SF-6D overestimation
relative to EQ-5D. In a survey of 389 patients with knee
pain, Barton et al. compared the EQ-5D and SF-6D for
practicality, validity and responsiveness [21]. The results
suggested that while the EQ-5D and SF-6D had largely
comparable practicality and construct validity, the SF-6D
could not discriminate between those who improved
post-intervention, and those who did not. In another
study in patients with knee pain due to inflammatory
arthritis [22], the EQ-5D was found to be more respon-
sive to deterioration in health, whereas the SF-6D was
more responsive to improvement in health. The results
showed that the SF-6D did not respond well to deterior-
ation in patients with established severe rheumatoid
arthritis, suggesting the SF-6D may be inappropriate for
patients with severe progressive disease. Comparison of
the EQ-5D and SF-6D across seven different conditions
or patient groups - chronic obstructive airways disease,
osteoarthritis, irritable bowel syndrome, lower back pain,
leg ulcers, post-menopausal women and the elderly - has
highlighted their general agreement in producing roughly
similar indices over this large and variable group [24].
However, this same analysis also illustrated the consider-
able disagreement between these two measures; the intra-
class correlation coefficient for the whole sample was 0.51,
and depending on the patient group, the difference be-
tween the measures ranged from 0.015 to 0.094 and the
intra-class correlation coefficient from 0.27 to 0.55.
The differences between EQ-5D and SF-6D are unsur-
prising since both measures vary in their descriptive sys-
tems, number of levels, scoring function, range of
utilities and recall period [23,24,26,27]. Both also have
differences in the valuation methods used; the EQ-5D
has been valued using time trade-off, while the SF-6D is
a derivative of the SF-36 and was valued using standard
gamble techniques [28].
While differences between these two instruments might
be unsurprising, any analyses that aim to compare these
different preference based measures of health are import-
ant because they inform debate and choice. Whether the
discrepancy between utility measures might influence
health economic analyses and policy decision-making is
not yet clear though some evidence suggests it might
[29,30]. In a simulation of over 100,000 patients with
rheumatoid arthritis, for example, Marra and colleagues
[29] showed that 91% of the simulations favoured the cost
utility of a specific treatment when using the HUI3 to cal-
culate QALYs. However, when using the EQ-5D, HUI2, or
the SF-6D utility values, the proportion of simulations that
favoured the cost utility of the treatment were 63%, 45%,
and 12%, respectively. A review by McDonough and col-
leagues concluded that choice of preference measure may
contribute to qualitatively different incremental cost-
effectiveness ratios (ICERs) under some circumstances
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ance appears to decrease, making the differences in
QALYs obtained using different methods potentially
meaningful. This could be particularly important for treat-
ments with long-term consequences and ICERs around
common thresholds.
At present the EQ-5D tends to provide a wider scoring
range and better completion rates than the SF-6D [23]
and tends to provide more favourable cost-effectiveness
ratios [30]. A new 5-level version of the EQ-5D has re-
cently been launched, the EQ-5D-5L [31] where the la-
bels for each of the dimensions are: no problems, slight
problems, moderate problems, severe problems and un-
able to/extreme problems. Studies to derive value sets
for the EQ-5D-5L are currently under development and
the potential usefulness has yet to be fully investigated.
However, it is anticipated that this new 5-level version
will have better discriminative capacity and sensitivity to
change and smaller ceiling effects than the EQ-5D-3L.
Conclusions
Differences between EQ-5D and SF-6D values can be
expected due to intrinsic differences in these indirect mea-
surements of utility. This analysis of patients with chronic
pain showed that the mean EQ-5D scores were lower than
mean SF-6D scores, however, the difference depended on
the quality of life status of a patient. EQ-5D seemed to
have higher construct validity and responsiveness in this
patient population. Namely, differences in mean utilities
between osteoarthritis patients with different severity levels
based on a disease-specific questionnaire (WOMAC) were
substantially larger with EQ-5D compared to SF-6D. Simi-
larly, EQ-5D detected larger differences between various
patient subgroups (including both osteoarthritis and low
back pain studies) with different AEs severity and pain re-
lief. Moreover, the measure of responsiveness was numer-
ically higher for EQ-5D, especially for subgroups with low
QOL levels at baseline.
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